Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
09 déc. 2011 18h30 HE
|
Transition Therapeutics Inc.
TORONTO, Dec. 9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition") (TSX:TTH) (Nasdaq:TTHI) today announces that Mr. Elie Farah, the Company's President and Chief Financial Officer,...
Transition Therapeutics Announces First Quarter Fiscal 2012 Financial Results
01 déc. 2011 16h01 HE
|
Transition Therapeutics Inc.
TORONTO, Dec. 1, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused biopharmaceutical company developing therapeutics for...
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST
29 nov. 2011 17h11 HE
|
Transition Therapeutics Inc.
TORONTO, Nov. 29, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Thursday, December 1, 2011 at 4:30 P.M....
Transition Therapeutics Completes US$5 Million Private Placement
22 nov. 2011 17h32 HE
|
Transition Therapeutics Inc.
TORONTO, Nov. 22, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced the closing of its previously disclosed private...
Transition Therapeutics Announces US$5 Million Private Placement
21 nov. 2011 06h31 HE
|
Transition Therapeutics Inc.
TORONTO, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced that it has entered into agreements to issue 3,703,703...
Transition Therapeutics Announces Publication of ELND005 Phase 2 Clinical Study Data in Alzheimer's Disease
27 sept. 2011 07h01 HE
|
Transition Therapeutics Inc.
TORONTO, Sept. 27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced that Phase 2 clinical study data of ELND005 in mild to...
Transition Therapeutics Announces Fiscal 2011 Year End Financial Results
19 sept. 2011 16h01 HE
|
Transition Therapeutics Inc.
TORONTO, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused biopharmaceutical company developing therapeutics...
Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2011 Financial Results on Monday, September 19th, at 4:30 P.M. EDT
16 sept. 2011 17h01 HE
|
Transition Therapeutics Inc.
TORONTO, Sept. 16, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Monday, September 19, 2011 at 4:30 P.M....
Transition Therapeutics to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
09 sept. 2011 08h01 HE
|
Transition Therapeutics Inc.
TORONTO, Sept. 9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that Elie Farah, President and Chief Financial Officer of...
Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting
15 juil. 2011 16h15 HE
|
Transition Therapeutics Inc.
TORONTO, July 15, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that data from the Phase 2 clinical trial of ELND005 in...